INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

19 Aug 2019

BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.

Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.

29 Apr 2019

Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing 

BTG plc today highlighted the VIEW VLU Registry interim study results, presented at the International Vein Congress in Miami, Florida. The interim findings confirm that Varithena® polidocanol injectable foam 1% shows promise in increasing the rate of wound healing.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

11 Aug 2014

First Varicose Vein Patient Treated with FDA-Approved Varithena® (polidocanol injectable foam) 1%

BTG International Inc. announces that the first varicose vein patient has been treated with Varithena®

11 Jun 2014

EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announces the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS® System (ACCESS PTS) Study.

23 May 2014

EkoSonic® Endovascular System receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA

EKOS Corporation, a BTG International group company announced that the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic® Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids.

30 Mar 2014

Acute Pulmonary Embolism Trial Confirms Safety and Efficacy of Ultrasound Accelerated Endovascular Thrombolysis

EKOS Corporation, a BTG International group company (BTG plc (LSE: BTG)), notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

21 Feb 2014

BTG announces Varithena™ data demonstrating continued improvement at one year at the American Venous Forum Annual Meeting

Today at the 26th Annual Meeting of the American Venous Forum in New Orleans, LA, Dr. Kenneth Todd, a Principal Investigator for VANISH-2, presented one-year data from the VANISH-2 clinical trial, one of the two pivotal trials for Varithena™ (polidocanol injectable foam).

BTG Products